Progress in the new drugs for the treatment of irritable bowel syndrome

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders with high prevalence rate，bringing severe financial burdens and psychological pressure to patients.Due to the complicated pathogenesis of IBS,current pathophysiologic mechanisms are based on the abnormalities of brain-gut axis.The continuous reasearches on various neurotransmitters and receptors，designed as targets，are accompanied with a hope of finding new durgs.This review summarizes the research situation,clinical efficacy and safety of various types of IBS new drugs,which includes the following targets:5-hydroxytryptamine receptor,guanylate cyclase C receptor,chloride channel,glucagon-like peptide-1 receptor,opiate receptor,cholecystokinin-1 receptor and benzodiazepine receptor.